228 related articles for article (PubMed ID: 37348193)
1. Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
Malani Shukla N; Casper TC; Ness J; Wheeler Y; Chitnis T; Lotze T; Gorman M; Benson L; Weinstock-Guttmann B; Aaen G; Rodriguez M; Tillema JM; Krupp L; Schreiner T; Mar S; Goyal M; Rensel M; Abrams A; Rose J; Waltz M; Liu T; Manlius C; Waubant E;
Pediatr Neurol; 2023 Aug; 145():125-131. PubMed ID: 37348193
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Spelman T; Simoneau G; Hyde R; Kuhelj R; Alroughani R; Ozakbas S; Karabudak R; Yamout BI; Khoury SJ; Terzi M; Boz C; Horakova D; Kubala Havrdova E; Weinstock-Guttman B; Patti F; Altintas A; Mrabet S; Gouider R; Inshasi J; Shaygannejad V; Eichau S; Ward WL; Butzkueven H;
Neurology; 2024 Apr; 102(7):e208114. PubMed ID: 38447093
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
[TBL] [Abstract][Full Text] [Related]
5. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.
Krysko KM; Graves J; Rensel M; Weinstock-Guttman B; Aaen G; Benson L; Chitnis T; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Rodriguez M; Rose J; Waltz M; Charles Casper T; Waubant E;
Neurology; 2018 Nov; 91(19):e1778-e1787. PubMed ID: 30333163
[TBL] [Abstract][Full Text] [Related]
6. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
Jakimovski D; Awan S; Eckert SP; Farooq O; Weinstock-Guttman B
CNS Drugs; 2022 Jan; 36(1):45-59. PubMed ID: 34940954
[TBL] [Abstract][Full Text] [Related]
7. Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
Solmaz I; Acar Ozen P; Parlak S; Tuncer A; Anlar B
Eur J Paediatr Neurol; 2022 Jul; 39():110-115. PubMed ID: 35777190
[TBL] [Abstract][Full Text] [Related]
8. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
[TBL] [Abstract][Full Text] [Related]
11. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
[TBL] [Abstract][Full Text] [Related]
12. Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Agashivala N; Wu N; Abouzaid S; Wu Y; Kim E; Boulanger L; Brandes DW
BMC Neurol; 2013 Oct; 13():138. PubMed ID: 24093542
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
14. Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Moccia M; Affinito G; Berera G; Marrazzo G; Piscitelli R; Carotenuto A; Petracca M; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
J Neurol; 2022 Dec; 269(12):6504-6511. PubMed ID: 35953597
[TBL] [Abstract][Full Text] [Related]
15. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
[TBL] [Abstract][Full Text] [Related]
16. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
17. Delayed initiation of disease modifying therapy increases relapse frequency and motor disability in pediatric onset multiple sclerosis.
Jafarpour S; Pinto S; Vu MH; Khoshnood MM; Ahsan N; Saucier LE; Santoro JD
Mult Scler Relat Disord; 2024 Jul; 87():105669. PubMed ID: 38749351
[TBL] [Abstract][Full Text] [Related]
18. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
19. Multiple Sclerosis, Disease-Modifying Therapies, and Infections.
Langer-Gould AM; Smith JB; Gonzales EG; Piehl F; Li BH
Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813594
[TBL] [Abstract][Full Text] [Related]
20. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
